SN-38

For research use only. Not for use in humans.

目录号:S4908 别名: NK012

SN-38 Chemical Structure

CAS No. 86639-52-3

SN-38 (NK012)是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 794.43 现货
RMB 742.35 现货
RMB 3013.44 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SN-38发表文献35篇:

产品安全说明书

ADC Cytotoxin抑制剂选择性比较

生物活性

产品描述 SN-38 (NK012)是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。
靶点
Topo I [1]
(Cell-free assay)
体外研究

SN-38是伊立替康盐酸盐(CPT-11)的生物活性代谢物。SN-38引起DNA拓扑异构酶I的抑制最强,其次是CPT,然后是CPT-11。 CPT-11剂量依赖性地转移宽松的DNA在切口的DNA的方向上的位置,但SN-38和CPT对宽松的DNA的位置没有影响。SN-38的剂量依赖性和时间依赖性地抑制DNA的合成。 SN-38的各自的IC50值,在DNA合成是0.077微米。SN-38的细胞RNA合成的抑制作用小于对DNA合成和它不抑制蛋白质的合成。 SN-38对P388细胞造成频繁的DNA单链断裂。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human DU145 prostate cell line Mm\rVJJwdGmoZYLheIlwdiCjc4PhfS=> NIfFO4RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KHC{b4P0ZZRmKGOnbHygcIlv\SxiSVO1NF0yOyCwTR?= Mk\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human MCF-7 breast cell line M2\4V3Bzd2yrZnXyZZRqd25iYYPzZZk> NWLRR3NCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2YuPyCkcnXhd5Qh[2WubDDsbY5mNCCLQ{WwQVAvOzdizszN M4LISVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEm4NlE3Lz5zMES5PFIyPjxxYU6=
human SKOV-3 ovarian cell line NYTW[2F{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NX\odIxtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT29XNTNib4\hdolidiClZXzsJIxqdmVuIFnDOVA:OC55MjFOwG0> NXLRdHRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0PVgzOTZpPkGwOFk5OjF4PD;hQi=>
human breast cancer cell line (SK-BR-3) M1nBWWN6fG:2b4jpZ:Kh[XO|YYm= M4nEOGlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG|dDDjZY5k\XJiY3XscEBtcW6nIDjTT{1DWi1|KTygTWM2OD12IH7N MnfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (H128) MYfDfZRwfG:6aXRCpIF{e2G7 NXrqWnF6UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdHWwZzDjZY5k\XJiY3XscEBtcW6nIDjINVI5MSxiSVO1NF03KG6P NXGyV3BYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human stomach cancer cell line (MKN45) MnnpR5l1d3SxeHnjxsBie3OjeR?= MXHJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDzeI9u[WOqIHPhcoNmeiClZXzsJIxqdmViKF3LUlQ2MSxiSVO1NF05KG6P NFn4bnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human ovarian cancer cell line (SK-OV-3) M4\FeGN6fG:2b4jpZ:Kh[XO|YYm= NVXCfXpPUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdCCuaX7lJEhUUy2RVj2zLUwhUUN3ME2xNUBvVQ>? NWmxbYxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human colon cancer cell line (WiDr) MUPDfZRwfG:6aXRCpIF{e2G7 NHjVZoRKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscEBtcW6nIDjXbWRzMSxiSVO1NF0yPCCwTR?= NFvwbYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human lung cancer cell line (A549) MmLvR5l1d3SxeHnjxsBie3OjeR?= Ml\CTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiDNUS5LS=> NWK5R4tMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
NSCLC-H460 MmO3R5l1d3SxeHnjxsBie3OjeR?= MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDuc44ue22jbHytZ4VtdCCudX7nJINiemOrbn;tZUBk\WyuIHzpcoUhUDR4MDCoUnNEVENvSES2NEktKEmFNUC9PFAhdk1? NGnye4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUW2N|kzPSd-MUG1OlM6OjV:L3G+
PC-3 carcinoma cell line NWfGU2doT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk\HR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHfyc5d1cCCxZjDoeY1idiCycn;zeIF1\SCSQz2zJINiemOrbn;tZUBk\WyuIHzpcoUtKEmFNUC9N|UvPiCwTR?= M2rISlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NEW0NlMxLz5zNUS1OFI{ODxxYU6=
human HCT116 colon cancer cell line MkHXSpVv[3Srb36gZZN{[Xl? NY\oWWt3UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOxbH;uJINidmOncjDj[YxtKGyrbnWsJGlEPTB;NzDuUS=> M3;zRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OEC4OFU3Lz5zNUiwPFQ2PjxxYU6=
human Bel-7402 liver cancer cell line NUXYdWN{TnWwY4Tpc44h[XO|YYm= NUTSXIFkUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbJVu[W5iQnXsMVc1ODJibHn2[ZIh[2GwY3XyJINmdGxibHnu[UwhUUN3ME2zMlE6KM7:TR?= NY[1cJZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human tumor HL60 cell-line NYDae4xITnWwY4Tpc44h[XO|YYm= M3izZ|Mh\GG7cx?= MUnJck13cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25iZn;yJIh2dWGwIIT1cY9zKEiONkCgZ4VtdC2uaX7lJJdieyCmZYTldo1qdmWmIIXzbY5oKFOUQjDhd5NigSCjZoTldkA{KGSjeYOgc4YhcW6ldXLheIlwdixiSVO1NF0yQSCwTR?= MnzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7MUO5PVYoRjF3OUGzPVk3RC:jPh?=
human H460 cell M2\ndmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUfuTZQ6UW6qaXLpeIlwdiCxZjDoeY1idiCKNE[wJINmdGxiZ4Lve5RpNCCLQ{WwQVgxKG6P MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NFYoRjF4OUGzO|A3RC:jPh?=
MDA-MB-435 MUTGeY5kfGmxbjDhd5NigQ>? NXjkUW1NUW6qaXLpeIlwdiCjZ3HpcpN1KE2GQT3NRk01OzViUzDoeY1idiCkcnXhd5Qh[2GwY3XyJINmdGy|IHnuJJRp\SCjYoPlcoNmKG:oIHHsZpVucW5uIFnDOVAhRSByLkCwOUDPxE1w NWqwRllbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOVI5ODJpPkGxNFUzQDB{PD;hQi=>
MDA-MB-435 NX\nc3k{TnWwY4Tpc44h[XO|YYm= MkDMTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBxemW|ZX7j[UBw\iB|MDDt[{9uVCCKU1GsJGlEPTBiPTCwMlA2KM7:TT6= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
PC-6/SN2-5H MYfGeY5kfGmxbjDhd5NigQ>? NVX1bZA4XFChVGLBUnNRV1KWRWK6JJVxfGGtZTDpckBu\W2kcnHu[UB3\XOrY3zlJIZzd21iUFOtOk9UVjJvNVigZ4VtdHNuIFvtJF0hPCEQvF2u M4TrV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNki4PVgzLz5zMU[4PFk5OjxxYU6=
HT-29 M2[1SGZ2dmO2aX;uJIF{e2G7 MV7JckB3cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25icnXxeYlz\WRiYXfhbY5{fCCKVD2yPUBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOsJGlEPTBiPTCwMlAzPzNizszNMi=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZzN{myO{c,OTJ4MUe5Nlc9N2F-
SaoS2 MYnGeY5kfGmxbjDhd5NigQ>? NYTtd2k6XFChVGLBUnNRV1KWRWK6JIRzfWdicnXzbZN1[W6lZTjJcYF1cW6rYjDt[ZN6dGG2ZTmgbY4hSkOUUD3lfJBz\XO|aX7nJHNid1N{IHPlcIx{NCCLQ{WwJF0hOC5zN{[g{txONg>? M3jueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MEW5PFgyLz5zNUC1PVg5OTxxYU6=
DU145 MlflRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{DtNVk3KGi{cx?= MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODB2IN88UU4> NFi5fJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO|YyPDF:L3G+
MIA PaCa NFnXd3FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXu5OkBpenN? NH7X[W9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRUBR[UOjIHPlcIx{KGGodHXyJFk3KGi{czygTWM2OCB;IECuNFA3KM7:TT6= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
HT29 NF[0NmRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVvzR2VOQTZiaILz MmXpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODF{IN88UU4> M2DKV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
H460 M2myZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVHlc5RHOSCqch?= M1\kNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5{MjFOwG0v M{X4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEK0NVM{Lz5zOESyOFE{OzxxYU6=
HT29 NXXRS2pDSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NX[weXVyOSCqch?= NVXvU3doSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIFnfGW{IEGgbJIhd2ZiZIL1[{BmgHCxc4Xy[UBu\WG|dYLl[EBi\nSncjC3NkBpenNuIFnDOVAhRSByLk[3JO69VS5? NF7DOHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESyOFE{Oyd-MUi0NlQyOzN:L3G+
HT29 NIf6TZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= Mn3RNUBpeg>? NUfTeppvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS1KSIH;2[ZJmgHC{ZYPzbY5oKG2rdH;4ZY51em:wZT3y[ZNqe3SjboSgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOTFwNTFOwG0v NV;4dnEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN|PD;hQi=>
H460 MWnDfZRwfG:6aXPpeJkh[XO|YYm= NXzyelF4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyxiSVO1NEA:KDBwMkKg{txONg>? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR|NEG1N{c,OTh2M{SxOVM9N2F-
A549 MkHUR5l1d3SxeHnjbZR6KGG|c3H5 MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KFOUQjDt[ZRpd2RuIFnDOVAhRSByLkC4JO69VS5? NVnJdZc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5PFY5ODdpPkG4PVg3QDB5PD;hQi=>
HT-29 MXnDfZRwfG:6aXPpeJkh[XO|YYm= NYrWUoYyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYomgV3JDKG2ndHjv[EwhUUN3MDC9JFAvOTJizszNMi=> Mo\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
PC6 MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mnz1OkBl[Xm| NIDqUldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDOkBk\WyuczDjZZJzgWmwZzDwVmMh[W[2ZYKgOkBl[Xm|LDDJR|UxKD1iMD6wNFA1OyEQvF2u NYLwRlNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR|PD;hQi=>
HCT116 MkO0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYGzJIRigXN? MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUCgQUAxNjByMEW1JO69VS5? NWnI[JVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR|PD;hQi=>
QG56 MoXaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1\ub|Mh\GG7cx?= MnXNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCTR{W2JINmdGy|IHHmeIVzKDNiZHH5d{whUUN3MDC9JFAvODB{ODFOwG0v NESwWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK1OFg1Oyd-MUmyOVQ5PDN:L3G+
NCI-H460 MoXLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3nLSFMh\GG7cx?= Mm\GRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVAhRSByLkCwN|Mh|ryPLh?= M1H4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
BCRP NXrRT45RSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{PBeFYh\GG7cx?= NGP0dnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDOkBmgHC{ZYPzbY5oKEKFUmCgZ4VtdHNiYX\0[ZIhPiCmYYnzMEBKSzVyIE2gNE4xODVzIN88UU4> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
KB3-1 NIXzb3VEgXSxdH;4bYNqfHliYYPzZZk> MX20JIRigXN? MnPPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCvZYToc4QtKEmFNUCgQUAxNjByNDFOwG0v M2\HZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{CzN|A3Lz5zOUOwN|MxPjxxYU6=
KBV1 NUHKUoRvS3m2b4TvfIlkcXS7IHHzd4F6 M13BS|Qh\GG7cx?= NIPlbm1EgXSxdH;4bYNqfHliYXfhbY5{fCCPRGKxJI93\XKneIDy[ZN{cW6pIHj1cYFvKEuEVkGgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KE2WVDDt[ZRpd2RuIFnDOVAhRSByLkC0OkDPxE1w M3SzZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{CzN|A3Lz5zOUOwN|MxPjxxYU6=
KBH5.0 MX;DfZRwfG:6aXPpeJkh[XO|YYm= NH7R[pc1KGSjeYO= Mlq0R5l1d3SxeHnjbZR6KGGpYXnud5QhSkOUUDDveoVz\XiycnXzd4lv\yCqdX3hckBMSkh3LkCgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KE2WVDDt[ZRpd2RuIFnDOVAhRSByLkOg{txONg>? NUW4OYRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N|A{OzB4PD;hQi=>
NCI-H460 M2\RfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYrsdYpQOSCqch?= NHHNPGdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJJNpd3K2IITldo0h\Xiyb4P1doUh\m:{IEGgbJIhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHnuJIRzfWdvZoLl[UBu\WSrdX2sJGlEPTBiPTCwMlE{KM7:TT6= M{G5S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUOwO|IxLz5zOUWzNFczODxxYU6=
A549/ATCC MVvBcpRqfHWvb4KgZZN{[Xl? MVnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5M2FVS0NiY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFg5KM7:TT6= NXPNfphURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1OFE1QDNpPkG5OVQyPDh|PD;hQi=>
HT-29 MmnrRY51cXS3bX;yJIF{e2G7 NGixOG9CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxKD1iMD6xO{DPxE1w NHTwV4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ5Oyd-MUm1OFE1QDN:L3G+
gastric cancer cells Mn;NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4[wZ|czKGi{cx?= NFnOcpBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBo[XO2cnnjJINidmOncjDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OCB;IECuNFY3KM7:TT6= M3ey[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NFg6Lz5{MEi4OFA5QTxxYU6=
lung cancer cells MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjYO|IhcHK| NW\Rc2kxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdHWwZzDjZY5k\XJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSByLkC2OkDPxE1w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEC4PUc,OjB6OESwPFk9N2F-
colon cancer cells MkLDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUC3NkBpenN? M3;hfWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5? MkGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
HT-29 NUjpemRHS3m2b4TvfIlkcXS7IHHzd4F6 M2PBdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{NCCLQ{WwJF0hOC5yMEW5JO69VS5? NV\mcW9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A5PjRpPkKxOFcxQDZ2PD;hQi=>
A549 MVjDfZRwfG:6aXPpeJkh[XO|YYm= MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE4xPDdizszNMi=> NHHKc2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS3NFg3PCd-MkG0O|A5PjR:L3G+
PC3 Ml\5R5l1d3SxeHnjbZR6KGG|c3H5 NVnobmFEPzJiaILz M3vsRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{BmgHC{ZYPzbY5oKGGucHjhOYJmfGF|IHnueIVoemmwIHHzd4V{e2WmIHHzJINmdGxic4Xyeol3[WxiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMECyOkDPxE1w MkDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
A2780 MkDtR5l1d3SxeHnjbZR6KGG|c3H5 NYPa[3BkPzJiaILz NFzVPW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByOTFOwG0v NFfKelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm1PVI1Pid-MkK5OVkzPDZ:L3G+
DU145 NWjsN|JlS3m2b4TvfIlkcXS7IHHzd4F6 MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{whUUN3MDC9JFAvODNizszNMi=> NVHye5JSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|g2PDVpPkKzOVc5PTR3PD;hQi=>
HT-29 M3Lr[GN6fG:2b4jpZ4l1gSCjc4PhfS=> NVXpeIVJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNuIFnDOVAhRSByLkCzJO69VS5? M4D6dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUe4OVQ2Lz5{M{W3PFU1PTxxYU6=
L1210 M1nyWmN6fG:2b4jpZ4l1gSCjc4PhfS=> NUfDdVBXS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVDF{MUCgZ4VtdHNuIFnDOVAhRSByLkC0JO69VS5? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
DU145 NVP0Z|RLS3m2b4TvfIlkcXS7IHHzd4F6 NIHsTog4OiCqcoO= MnjrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMD6xNUDPxE1w M3XpfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkKyPVgyLz5{M{[yNlk5OTxxYU6=
DU145 MomySpVv[3Srb36gZZN{[Xl? NXLFS2xxOC5zIITvJFAvPSC3TR?= MUWyOEBpenN? NEjhS5RKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hTFVzNEWgZ4VtdHNiYYPz[ZN{\WRiYYOgeZBz\We3bHH0bY9vKG:oIICyNZdi\jFiZYjwdoV{e2mxbjDheEAxNjFidH:gNE42KHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NGr4[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[yNlk5OSd-MkO2NlI6QDF:L3G+
A549 NI\TbotEgXSxdH;4bYNqfHliYYPzZZk> NXyyXIR{OyCmYYnz NVXxeVdsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB|IHThfZMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wNFI4OiEQvF2u NV3rTZhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
HCT116 MmrOR5l1d3SxeHnjbZR6KGG|c3H5 NFniOZI{KGSjeYO= NHn5OJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMzDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFMyKM7:TT6= NIHBfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HT-29 NIXJ[mVEgXSxdH;4bYNqfHliYYPzZZk> MofUN{Bl[Xm| NFzPTVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB|IHThfZMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6xNFY3PyEQvF2u NX;LVW1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
HCT116 NX30[XB4S3m2b4TvfIlkcXS7IHHzd4F6 M3S0R2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyxiSVO1NEA:KDBwMU[2JO69VS5? MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
MDA-MB-231 NGHidlNEgXSxdH;4bYNqfHliYYPzZZk> MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|LDDJR|UxKD1iMD6xO|Yh|ryPLh?= NXnCVZJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
A549 NUfRTnFjS3m2b4TvfIlkcXS7IHHzd4F6 NXOyR3g1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyxiSVO1NEA:KDBwMkW5JO69VS5? MljXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HEK293 NEHGS4REgXSxdH;4bYNqfHliYYPzZZk> M2P2cVczKGi{cx?= NYHlfo0yUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IFjFT|I6OyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVe1NEA:KDBwMEC1JO69VS5? MljKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{KwOVUoRjJ3MkeyNFU2RC:jPh?=
HCT116 NYO2cpNOS3m2b4TvfIlkcXS7IHHzd4F6 MUG3NkBpenN? Mo\sR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6wNFQzQCEQvF2u MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|NUO1PUc,OjV6M{WzOVk9N2F-
HT-29 M1:4[WN6fG:2b4jpZ4l1gSCjc4PhfS=> NFTmeGY4OiCqcoO= NF65R4hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFE5PTRizszNMi=> NHXDdlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVM2QSd-MkW4N|U{PTl:L3G+
HCT15 NGTBdGJEgXSxdH;4bYNqfHliYYPzZZk> MYe3NkBpenN? M4LZOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDF3IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCwPEDPxE1w Ml\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
U251 NUTpVW4zS3m2b4TvfIlkcXS7IHHzd4F6 NXnmT3Z{PzJiaILz Mof1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVI2OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMkGg{txONg>? MlXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
U87MG M4e3R2N6fG:2b4jpZ4l1gSCjc4PhfS=> NH3MZnQ4OiCqcoO= MlrhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMEOg{txONg>? NWj0cph[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
HT-29 MUnDfZRwfG:6aXPpeJkh[XO|YYm= MWm3NkBpenN? MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yNUSg{txONg>? M1u4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|YxLz5{N{C2NFc3ODxxYU6=
MCF7 NXLMR3U1S3m2b4TvfIlkcXS7IHHzd4F6 NX\xSWI2PzJiaILz MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjVzNTFOwG0v Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
MDA-MB-231 M1mzeWN6fG:2b4jpZ4l1gSCjc4PhfS=> NEexNnY4OiCqcoO= MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCxMlk4KM7:TT6= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
NCI-H460 Mof3R5l1d3SxeHnjbZR6KGG|c3H5 NWHtOWtQOjRiaILz Ml3FR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IH7vdo1wgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA2KM7:TT6= MmnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
NCI-H460 Mnz2R5l1d3SxeHnjbZR6KGG|c3H5 NHGwS4EzPCCqcoO= Moi4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh|ryPLh?= MlH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
HT-29 MYfDfZRwfG:6aXPpeJkh[XO|YYm= NEPLN|czPCCqcoO= NFTNRmpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJibn;ycY95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuO|Qh|ryPLh?= NX7ydZZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N|UxQTl5PD;hQi=>
HT-29 NXLEZW4yS3m2b4TvfIlkcXS7IHHzd4F6 NUTBdnNCOjRiaILz MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BxemW2cnXheIVlKG[xcjCyOEBpenNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55MTFOwG0v M{f5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460 MmLPR5l1d3SxeHnjbZR6KGG|c3H5 M1jsWVczKGi{cx?= NIn5N2xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigdoVlfWO2aX;uJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC0O{DPxE1w NIDJeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe0NFYyOyd-Mki3OFA3OTN:L3G+
NCI-H460 MnXRR5l1d3SxeHnjbZR6KGG|c3H5 Mmn2O|IhcHK| NUH1SYFiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJJJm\HWldHnvckB2dmSncjDuc5Jud3irYzDjc45lcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFUh|ryPLh?= M1m1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
HT-29 M3G1R2N6fG:2b4jpZ4l1gSCjc4PhfS=> MUe3NkBpenN? NXzqeIV3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEm2JO69VS5? NYftc5BwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O|QxPjF|PD;hQi=>
HT-29 MnjhR5l1d3SxeHnjbZR6KGG|c3H5 NFrVWFY4OiCqcoO= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghemWmdXP0bY9vKHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlEyQSEQvF2u NIHrbXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe0NFYyOyd-Mki3OFA3OTN:L3G+
TC32 MlO2dWhVWyCjc4PhfS=> NIfqT4RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= NXf2VlI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 M1zpVJFJXFNiYYPzZZk> NUWzUFlqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NHTIbY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MYnxTHRUKGG|c3H5 MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 M3rONZFJXFNiYYPzZZk> MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| M3nLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MWjxTHRUKGG|c3H5 NXjUU2FyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MYDxTHRUKGG|c3H5 NYXtTWxZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M2\HUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NV3vU|BYeUiWUzDhd5NigQ>? NH7CTWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 Mm\LdWhVWyCjc4PhfS=> NEHJXYJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MoPxdWhVWyCjc4PhfS=> NVLaTJBqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MmTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MXHxTHRUKGG|c3H5 NITvSXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MmPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NXHzfIJEeUiWUzDhd5NigQ>? M33V[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= M1f4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 M1jobpFJXFNiYYPzZZk> MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MXnxTHRUKGG|c3H5 NX;tPYEzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= MmXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MVXxTHRUKGG|c3H5 Mn;CdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? NYT2OWV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NHrwWFJyUFSVIHHzd4F6 M4XjeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MYTxTHRUKGG|c3H5 NIf0NIlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= NUTsV4lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NVXDS3lMeUiWUzDhd5NigQ>? MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MWTxTHRUKGG|c3H5 NHv6[VlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{ NWn1NFd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS Mmm1dWhVWyCjc4PhfS=> M{CwN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>? M1\xN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 M4THUJFJXFNiYYPzZZk> M{K0U5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NGnoeZVyUFSVIHHzd4F6 NHn2eYNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MUTxTHRUKGG|c3H5 NYDaWnhCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NUTNO41HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M2LkZpFJXFNiYYPzZZk> Ml7PdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NWf6RoZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NIXONGNyUFSVIHHzd4F6 M3vEVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NFXSXFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NFjVOVRyUFSVIHHzd4F6 M1O4[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
HCT116 NV3yNFEzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWTTd4szPzJiaILz NUjD[3BOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODByN{ig{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODFzNUS5Nkc,OzBzMUW0PVI9N2F-
A549 NGnwbpNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYe3NkBpenN? NWfaTXN[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCwMlAxOTZ{IN88UU4> Ml3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzMUW0PVIoRjNyMUG1OFkzRC:jPh?=
MCF7 NY\iTnAxS3m2b4TvfIlkcXS7IHHzd4F6 MXy3NkBpenN? NEHNbJNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6wNFAyKM7:TT6= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4OUCzPEc,OzBzNkmwN|g9N2F-
A549 NE\TflJEgXSxdH;4bYNqfHliYYPzZZk> M3PZTlczKGi{cx?= NEXMSnhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6yJO69VS5? Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN|goRjNyMU[5NFM5RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / Topo I ; 

PubMed: 18509065     


Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.

18509065
Growth inhibition assay
Cell viability; 

PubMed: 25759163     


(A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.

25759163
体内研究 口服给药后,SN-38的最高浓度出现在1小时后,并且未结合的SN-38内酯在小鼠血浆在1000纳克/毫升时百分比是3.4 +/- 0.67%,而在100纳克/毫升的未结合的百分比是1.18 +/- 0.14%。在含人类神经母细胞瘤的裸鼠中SN-38内酯的AUC大于在非肿瘤息动物的量。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

拓扑异构酶I检测:

一个单位(本研究的条件下,使0.5微克SV40 DNA完全松弛的最小量)拓扑异构酶I, 0.5微升的测试化合物,和0.5μg SV40的DNA按顺序加入反应缓冲液中,它是由25毫摩尔Tris -盐酸(pH值7.5),50 mM的KCl, 5 mM的氯化镁,0.25毫摩尔EDTA二钠盐,0.25 mM二硫苏糖醇,15 μg/毫升牛血清白蛋白和5 %的甘油。然后,将反应混合物(50 μL)在37 ℃温育10分钟,并将该反应通过7.5 μL 溶液在37 ℃温育30分钟终止, 1%十二烷基硫酸钠, 20 mM的EDTA二钠盐,和0.5 mg/mL 蛋白酶K。 样品和5 μL 的上样缓冲液混合,上样缓冲液包含10 mM磷酸氢二钠,31.3%蔗糖,0.3%溴酚蓝。松弛(Ir形式)的DNA从超螺旋(形式I)中分离,带切口的( II型)的DNA通过电泳在0.8%琼脂糖凝胶分离,电泳是在在2 μg/mL chloroquine, 10 mM EDTA, 30 mM 磷酸氢二钠存在下在50毫安和20 V条件下进行17小时。电泳后,将凝胶用0.05%溴化乙锭染色并用UV光(302纳米)拍摄。 DNA量是用密度计进行定量。
细胞实验:[3]
- 合并
  • Cell lines: A-172, U-87和LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 小时
  • Method: MTT 检测
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 21 mg/mL (53.51 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 392.4
化学式

C22H20N2O5

CAS号 86639-52-3
储存条件 粉状
溶于溶剂
别名 NK012

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04866641 Not yet recruiting Drug: T-1201 Injection 100 mg Kit Advanced Solid Tumor Taivex Therapeutics Corporation July 5 2021 Phase 1
NCT04617522 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced or Metastatic Solid Tumor|Liver Failure Gilead Sciences April 6 2021 Phase 1
NCT03995706 Recruiting Drug: Sacituzumab Govitecan Glioblastoma The University of Texas Health Science Center at San Antonio|Gilead Sciences July 17 2019 Early Phase 1
NCT03245450 Completed Drug: Eribulin mesilate|Drug: Irinotecan hydrochloride Refractory or Recurrent Solid Tumors|Rhabdomyosarcoma|Non-Rhabdomyosarcoma Soft Tissue Sarcoma|Ewing Sarcoma Eisai Inc. February 22 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买SN-38 | SN-38供应商 | 采购SN-38 | SN-38价格 | SN-38生产 | 订购SN-38 | SN-38代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID